Insulin Market in the US and Europe 2016-2020

2016-05-05
Price :
Published : May-2016
No. of Pages : 95

Beta cells of the pancreas produce insulin, a hormone that regulates blood glucose levels, by stimulating cells to absorb glucose from the blood. In the cells, glucose is converted into energy, which is used by tissues and muscles to perform their physiological functions. This process is restricted in people with diabetes, resulting in the accumulation of glucose in the blood. This condition is known as hyperglycemia; it damages body tissues over a period, leading to life-threatening health complications such as diabetic retinopathy and diabetic nephropathy. In type 1 diabetes or gestational diabetes, the immune system attacks the pancreatic cells, resulting in little or no insulin production. In type 2 diabetes, the body does not produce sufficient insulin to regulate blood glucose levels. In both type 1 and type 2 diabetes, the individual requires daily doses of insulin along with other medications, depending on the condition. Different types of insulin products, such as human insulin and insulin analogs, are available for insulin replacement therapy.

The analysts forecast insulin market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:

  • US
  • Europe

The report, Insulin Market in the US and Europe 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Sanofi
  • Novo Nordisk
  • Eli Lilly

Other prominent vendors

  • Adocia
  • Biocon
  • Biodel
  • Biogenomics
  • Boehringer Ingelheim
  • Dance Biopharm
  • Diasome Pharmaceuticals
  • Exsulin
  • Generex
  • Lexicon Pharmaceuticals
  • Ligand Pharmaceuticals
  • MannKind
  • Macrogenics
  • Merck
  • Melior Pharmaceuticals
  • Metabolic Solutions Development Company
  • NGM Biopharmaceuticals
  • NuSirt Biopharma
  • Oramed Pharmceuticals
  • PhaseBio Pharmaceuticals
  • Pfizer
  • Thermalin Diabetes
  • Tolerion
  • VeroScience
  • vTv Therapeutics
  • Wockhardt
  • XOMA

Market driver

  • Advances in insulin delivery technology
  • For a full, detailed list, view our report

Market challenge

  • Complexity of insulin production
  • For a full, detailed list, view our report

Market trend

  • Increasing price of insulin drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

EpiCast Report: Alzheimer’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2026 Summary Alzheimer's disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized by the death of brain cells, which leads to a progressive decline in memory and cognitive abilities, such as thinking, language, and learning capacity (NIA, 2017). AD is the most common cause of dementia in people age 60 years and older, and accounts for approximately 75% of the total dementia cases worldwide. To forecast the total prevalent cases of AD in adults ages 60 years and older in the 7MM during the forecast period (2016-2026), our epidemiologists identified country-specific population-based studies that used the diagnostic criteria based on the Diagnostic and Sta......
$3995

EpiCast Report: Epilepsy – Epidemiology Forecast to 2026

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026 Summary Epilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal activity in the brain (WHO, 2017). It is one of the most common neurological conditions globally (WHO, 2017). Epilepsy can start at any age and can be a life-long condition. It is diagnosed after a patient has suffered a seizure and is referred to a specialist, where a description of the symptoms before the seizure and the seizure itself are used for a diagnosis (NHS, 2014). In the 7MM, the lifetime diagnosed prevalent cases of epilepsy will increase from almost 11 million cases in 2016 to just over 11.5 million cases in 2026, at an Annual Growth Rate (AGR) of almost 0.5% pe......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for August 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report p......
$1000

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Argentina

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina Summary Pharmaceutical market increased from over US$3 Billion in 2009 to around US$6.5 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of nearly 10%. It is expected to cross US$10 Billion in 2021 at a CAGR of about 10%. In 2009, the medical device market was valued at just over US$1 Billion. It grew at a CAGR of 4% between 2009 and 2016 and reached around US$1.3 Billion. It is expected to grow at a CAGR of about 5%, from around US$1.4 Billion in 2017 to over US$1.7 Billion in 2021. Argentina is the third-largest pharmaceutical market in Latin America after Brazil and Mexico. With a relatively low-cost base and high-quality professionals in the biotechnology sector, Argentina is home to over 130 ......
$1995

EpiCast Report: Melanoma – Epidemiology Forecast to 2026

EpiCast Report: Melanoma - Epidemiology Forecast to 2026 Summary Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin (WHO, 2014). Melanocytes are embryological derivatives of neural crest tissue, and as such, any region of the body that is a derivative of the neural crest and contains melanocytes-namely areas of skin, meninges, mucous membranes, esophagus, and eyes-can develop melanoma (Komarnicky-Kocher and Alite, 2013). In the 7MM, our epidemiologists forecast the diagnosed incident cases of melanoma to increase to over 200,000 cases by 2026, at an Annual Growth Rate (AGR) of almost 2.5%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagn......
$3995

EpiCast Report: Crohn’s Disease – Epidemiology Forecast to 2026

EpiCast Report: Crohn's Disease - Epidemiology Forecast to 2026 Summary Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. While any part of the gastrointestinal tract can be affected, inflammation is most commonly found at the end of the small intestine (ileum), and the start of the large intestine (colon). The disease course of CD is characterized by periods of remission followed by periods of relapse, the length and severity of which differ from case to case (CDC, 2014; NHS, 2015). Inflammation in CD can result in severe scarring and narrowing of the parts of the bowel. Our epidemiologists forecast that the diagnosed incident cases of CD in the 7MM will increase from 70,985 in 2016 to 74,712 in 2026 a......
$3995

Hyperbilirubinemia Global Clinical Trials Review, H2, 2017

Hyperbilirubinemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperbilirubinemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperbilirubinemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperbilirubinemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical t......
$2500

Hyperphosphatemia Global Clinical Trials Review, H2, 2017

Hyperphosphatemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperphosphatemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperphosphatemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperphosphatemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trial......
$2500

Hypercalcemia Global Clinical Trials Review, H2, 2017

Hypercalcemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hypercalcemia Global Clinical Trials Review, H2, 2017" provides an overview of Hypercalcemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hypercalcemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Hyperinsulinemia Global Clinical Trials Review, H2, 2017

Hyperinsulinemia Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hyperinsulinemia Global Clinical Trials Review, H2, 2017" provides an overview of Hyperinsulinemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperinsulinemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials da......
$2500